Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

News

News

Select Year
Search News

Found 505 Results

Page 38 of 51« First «...10 20 30...36 373839 40...50...»Last »

January 8, 2016

DBV Technologies Announces 2016 Financial Calendar

January 7, 2016

DBV Technologies Presents its Half-year Statement of the Liquidity Contract

December 10, 2015

First Experimental Results for the Treatment of Colitis with Viaskin^® will be presented at the Crohn’s & Colitis Foundation of America’s 2015 Advances in IBD Conference (AIBD)

December 7, 2015

DBV Technologies Announces Initiation of Phase III Study of Viaskin^® Peanut for the Treatment of Peanut Allergic Children

November 18, 2015

DBV Technologies to Present Preclinical Data on its Viaskin^® Technology for RSV Vaccination at the 2015 RSV Vaccines for the World Meeting

November 12, 2015

DBV Technologies Announces Enrollment of First Patient in Phase IIA Study in Pediatric Eosinophilic Esophagitis

November 3, 2015

DBV Technologies Reports Interim Financial Results for the third quarter of 2015

October 22, 2015

DBV Technologies Announces the Appointment of Michael J. Goller to its Board of Directors

October 14, 2015

DBV Technologies Announces First Patient Enrolled in Phase II Study of Viaskin Milk

October 5, 2015

Follow-Up Study of Viaskin^® Peanut Shows Significant Increase in Peanut Consumption and Treatment Benefit in Peanut Allergic Children

Page 38 of 51« First «...10 20 30...36 373839 40...50...»Last »

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Cookies Policy

Scroll to Top